Eli Lilly acquires SiteOne Therapeutics to advance treatment for chronic pain - PharmaTimes Global biopharma Eli Lilly will acquire SiteOne Therapeutics, a biotech dedicated to the development of non-opioid medicines to treat pain and other neuronal

#EliLilly #SiteOneTherapeutics #chronicpain #biopharma #biotech #nonopioidmedicines #pain #neuronalhyperexcitabilitydisorders #SiteOne #STC004 #addiction #opioids #painmanagement #sensoryhyperexcitabilitydisorders #chroniccough #chronicocularsurfacepain
pharmatimes.com/news/eli-lil...